Praxis Precision Medicines, Inc.(PRAX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PRAX Praxis Precision Medicines, Inc.

Post-Mkt 12-11 17:05:31 EST

267.28

+5.70

+2.18%

盘后271.00

+3.72+1.39%

17:01 EST

High271.69	Low252.20	Vol514.02K
Open261.40	D1 Closing261.58	Amplitude7.45%
Mkt Cap6.68B	Tradable Cap5.29B	Total Shares25.01M
T/O136.36M	T/O Rate2.60%	Tradable Shares19.79M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"PRAX","market":"US","secType":"STK","nameCN":"Praxis Precision Medicines, Inc.","latestPrice":267.28,"timestamp":1765486800000,"preClose":261.58,"halted":0,"volume":514024,"hourTrading":{"tag":"盘后","latestPrice":271,"preClose":267.28,"latestTime":"17:01 EST","volume":4466,"amount":1193679.8489,"timestamp":1765490467124},"delay":0,"floatShares":19790700,"shares":25007171,"eps":-12.922727,"marketStatus":"Post-Mkt","change":5.7,"latestTime":"12-11 17:05:31 EST","open":261.4,"high":271.69,"low":252.2,"amount":136361808.23104,"amplitude":0.074509,"askPrice":275,"askSize":8,"bidPrice":264,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-12.922727,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1765501200000},"marketStatusCode":4,"adr":0,"listingDate":1602820800000,"exchange":"NASDAQ","adjPreClose":261.58,"preHourTrading":{"tag":"盘前","latestPrice":259.5,"preClose":261.58,"latestTime":"09:28 EST","volume":197,"amount":51260.10526,"timestamp":1765463283046},"postHourTrading":{"tag":"盘后","latestPrice":271,"preClose":267.28,"latestTime":"17:01 EST","volume":4466,"amount":1193679.8489,"timestamp":1765490467124},"volumeRatio":0.361543,"impliedVol":0.7458,"impliedVolPercentile":0.052},"requestUrl":"/m/hq/s/PRAX","defaultTab":"news","newsList":[{"id":"2590415325","title":"Praxis Precision Medicines - to File a Nda for Relutrigine in Scn2a and Scn8a Dees in Early 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2590415325","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590415325?lang=en_us&edition=fundamental","pubTime":"2025-12-12 05:24","pubTimestamp":1765488298,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nFWN3XH1BN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0109394709.USD","LU0320765992.SGD","BK4139","PRAX","LU0889565916.HKD"],"gpt_icon":0},{"id":"2590150145","title":"Praxis Precision Medicines Reports Relutrigine Shows Significant Seizure Reduction in EMBOLD Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2590150145","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590150145?lang=en_us&edition=fundamental","pubTime":"2025-12-11 21:00","pubTimestamp":1765458039,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines Inc. announced plans to file a New Drug Application  for relutrigine in early 2026, following successful discussions with the FDA. The application will be based on efficacy and safety data from the EMBOLD study, which demonstrated that relutrigine provided statistically significant and clinically meaningful improvements in children with SCN2A and SCN8A developmental and epileptic encephalopathies . The company reported that relutrigine showed robust, short- and long-term improvements in motor seizures and maintained seizure freedom in some patients, alongside a favorable safety profile. These results have already been collected and discussed with the FDA.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Praxis ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL1Pk1v4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","IE00B64PRP62.GBP","LU0889565916.HKD","PRAX","BK4112","BK4585","LU2095319765.USD","LU0314104364.USD","SG9999014013.SGD","IE00BKPKM429.USD","IE00BGHQF748.EUR","SG9999014021.USD","SG9999014039.USD","LU0320765992.SGD","BK4588","LU2210150020.SGD","LU2210149790.SGD","BK4139","IE00B3QW5Z07.USD","NDAQ","SG9999014005.SGD"],"gpt_icon":0},{"id":"2590166035","title":"Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2590166035","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590166035?lang=en_us&edition=fundamental","pubTime":"2025-12-11 21:00","pubTimestamp":1765458000,"startTime":"0","endTime":"0","summary":"EMBOLD data to serve as basis of efficacy and safety following discussion with the FDABOSTON, Dec.  11, 2025  (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biop","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/11/3203828/0/en/Praxis-Precision-Medicines-Announces-Plans-to-File-an-NDA-for-Relutrigine-in-SCN2A-and-SCN8A-Developmental-and-Epileptic-Encephalopathies-in-Early-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNS","LU0109394709.USD","ASO","BK4561","PRAX","LU0320765992.SGD","ODD","BK4139","BK4183","IE0009354923.USD","LU0889565916.HKD","BK4135","BK4200"],"gpt_icon":0},{"id":"2590321401","title":"BRIEF-Praxis Precision Medicines Announces Alignment With FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2590321401","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590321401?lang=en_us&edition=fundamental","pubTime":"2025-12-10 05:05","pubTimestamp":1765314307,"startTime":"0","endTime":"0","summary":"BRIEF-Praxis Precision Medicines Announces Alignment With FDA Dec 9 (Reuters) - Praxis Precision Medicines Inc PRAX.O:PRAXIS PRECISION MEDICINES ANNOUNCES ALIGNMENT WITH FDA ON SIMPLIFIED AND ACCELERA","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nFWN3XF0QF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU0889565916.HKD","LU0320765992.SGD","PRAX","LU0109394709.USD"],"gpt_icon":0},{"id":"2590321975","title":"Praxis Precision Medicines Inc:  FDA Agreed to Proposed Changes to Embrave3 Trial Design to Be a Single-Arm, Baseline-Controlled Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2590321975","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590321975?lang=en_us&edition=fundamental","pubTime":"2025-12-10 05:01","pubTimestamp":1765314081,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nFWN3XF0QF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0109394709.USD","LU0320765992.SGD","BK4139","PRAX","LU0889565916.HKD"],"gpt_icon":0},{"id":"2590219063","title":"Praxis Precision Medicines Announces Alignment With FDA on Simplified and Accelerated Registrational Pathway for Elsunersen in Early Onset Scn2a Developmental and Epileptic Encephalopathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2590219063","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590219063?lang=en_us&edition=fundamental","pubTime":"2025-12-10 05:01","pubTimestamp":1765314081,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nFWN3XF0QF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0889565916.HKD","BK4139","PRAX","LU0320765992.SGD","LU0109394709.USD"],"gpt_icon":0},{"id":"2590134321","title":"Praxis Precision Medicines Inc:  Topline Results From Ongoing Embrave Study (Part a, N=9) Expected in 1H 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2590134321","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590134321?lang=en_us&edition=fundamental","pubTime":"2025-12-10 05:01","pubTimestamp":1765314081,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nFWN3XF0QF:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0109394709.USD","LU0889565916.HKD","LU0320765992.SGD","BK4139","PRAX"],"gpt_icon":0},{"id":"2590321148","title":"Praxis Precision Medicines Converts EMBRAVE3 Trial to Single-Arm Study for Elsunersen in SCN2A-DEE","url":"https://stock-news.laohu8.com/highlight/detail?id=2590321148","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590321148?lang=en_us&edition=fundamental","pubTime":"2025-12-10 05:01","pubTimestamp":1765314070,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines Inc. announced that the U.S. Food and Drug Administration has agreed to the company's proposed changes to the EMBRAVE3 registrational trial for elsunersen in early-onset SCN2A developmental and epileptic encephalopathy . The trial has been converted from a double-blind, sham-controlled design to a single-arm, baseline-controlled study, reducing the enrollment target from 40 to 30 patients. All participants will receive elsunersen for 24 weeks, followed by an open-label extension. The primary analysis will focus on the change from baseline in countable motor seizures. Enrollment in EMBRAVE3 is accelerating, with topline results expected in 2026. Additionally, topline results from the ongoing EMBRAVE study  are anticipated in the first half of 2026. No study results have been presented yet.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nNDLbVtY2n:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","SG9999014021.USD","LU0314104364.USD","BK4585","BK4139","PRAX","NDAQ","IE00BGHQF748.EUR","LU2210150020.SGD","LU0889565916.HKD","BK4588","LU0320765992.SGD","LU0109394709.USD","SG9999014005.SGD","IE00B64PRP62.GBP","IE00BKPKM429.USD","IE00B3QW5Z07.USD","LU2095319765.USD","SG9999014013.SGD","SG9999014039.USD","BK4112"],"gpt_icon":0},{"id":"2590364375","title":"Praxis Precision Medicines (PRAX) Is Up 34.4% After Dual Neurology Milestones - Has The Bull Case Changed?","url":"https://stock-news.laohu8.com/highlight/detail?id=2590364375","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590364375?lang=en_us&edition=fundamental","pubTime":"2025-12-09 06:19","pubTimestamp":1765232365,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines recently reported positive efficacy results from the registrational cohort of its EMBOLD trial of relutrigine in rare developmental and epileptic encephalopathies, and completed a pre-NDA FDA meeting for ulixacaltamide in essential tremor, with an NDA filing targeted for early 2026.\nTogether, these programs highlight Praxis’s effort to build a focused neurology franchise that spans ultra-rare pediatric epilepsies and a large, underserved essential tremor...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-prax/praxis-precision-medicines/news/praxis-precision-medicines-prax-is-up-344-after-dual-neurolo","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-prax/praxis-precision-medicines/news/praxis-precision-medicines-prax-is-up-344-after-dual-neurolo","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0889565916.HKD","PRAX","LU0320765992.SGD","BK4139","LU0109394709.USD"],"gpt_icon":0},{"id":"2590662533","title":"Praxis Precision Medicines Inc: Monotherapy Study, Power3, Is on Track to Begin in First Half of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2590662533","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590662533?lang=en_us&edition=fundamental","pubTime":"2025-12-09 05:46","pubTimestamp":1765230409,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nFWN3XE1JQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0889565916.HKD","BK4139","LU0109394709.USD","LU0320765992.SGD","PRAX"],"gpt_icon":0},{"id":"2589035334","title":"Truist Raises Price Target on Praxis Precision Medicines to $500 From $360, Keeps Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2589035334","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589035334?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:01","pubTimestamp":1765198899,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines (PRAX) has an average rating of buy and mean price target of $374.20, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research fr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PRAX"],"gpt_icon":0},{"id":"2589735333","title":"Praxis Precision Medicines Reports 53% Seizure Reduction With Relutrigine in EMBOLD Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2589735333","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589735333?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:00","pubTimestamp":1765198849,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines Inc. announced clinical updates at the American Epilepsy Society Annual Meeting on December 6, 2025, highlighting positive results from the EMBOLD study of relutrigine in patients with developmental and epileptic encephalopathies . The results, already presented at the meeting, showed a 53% placebo-adjusted reduction in seizures and a 66% increase in motor seizure-free days over 16 weeks. Clinician and caregiver assessments indicated statistically significant improvements in alertness, communication, and seizure severity. Praxis stated that it will meet with the FDA to discuss next steps for a potential New Drug Application  for relutrigine and will determine NDA filing timing following the meeting. The company also reported completion of recruitment for the POWER1 pivotal study in focal onset seizures , with additional studies planned or ongoing.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PU","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDLbLN9L3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","LU0314104364.USD","IE00BKPKM429.USD","BK4585","BK4139","NDAQ","LU2095319765.USD","SG9999014039.USD","PRAX","IE00B64PRP62.GBP","IE00BGHQF748.EUR","LU0889565916.HKD","LU2210150020.SGD","LU0109394709.USD","IE00B3QW5Z07.USD","SG9999014013.SGD","SG9999014021.USD","LU2210149790.SGD","BK4588","BK4112","SG9999014005.SGD"],"gpt_icon":0},{"id":"2589010334","title":"Praxis Precision Medicines Inc : Needham Raises Target Price to $315 From $304","url":"https://stock-news.laohu8.com/highlight/detail?id=2589010334","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589010334?lang=en_us&edition=fundamental","pubTime":"2025-12-08 19:13","pubTimestamp":1765192409,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nFWN3XE0RV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0109394709.USD","BK4139","PRAX","LU0320765992.SGD","LU0889565916.HKD"],"gpt_icon":0},{"id":"2589733430","title":"Praxis Precision Med Is Maintained at Buy by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2589733430","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589733430?lang=en_us&edition=fundamental","pubTime":"2025-12-08 18:50","pubTimestamp":1765191000,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PRAX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 08, 2025 05:50 ET (10:50 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","PRAX","LU0109394709.USD","LU0320765992.SGD","BK4139"],"gpt_icon":0},{"id":"2589781231","title":"BUZZ-U.S. STOCKS ON THE MOVE-Omnicom, Albemarle, energy companies","url":"https://stock-news.laohu8.com/highlight/detail?id=2589781231","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589781231?lang=en_us&edition=fundamental","pubTime":"2025-12-06 03:14","pubTimestamp":1764962096,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Omnicom, Albemarle, energy companiesEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newslette","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nL6N3XB0IL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COO","EXE","FSLY","IOT","ZUMZ","OMC","LU1150488218.USD","AUB","RBRK","S","TE","CHPT","VSCO","ROL","FANG","ITT","EQT","INTS","AMLX","PKG","XOM","TARA","FCX","DBRG","CDE","AES","PRAX","BMEA","PSN","ULTA","LU0128525929.USD","HPE","LU0128525689.USD","TRMB","WBD","LUV","TTAN","SCCO","LU0320765646.SGD","DELL","HUM","HL","EUDA","ALB"],"gpt_icon":1},{"id":"2589145988","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2589145988","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589145988?lang=en_us&edition=fundamental","pubTime":"2025-12-06 02:12","pubTimestamp":1764958329,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines (PRAX) reported positive trial results late Thursday of relutrigine to treat patients with SCN2A and SCN8A developmental and epileptic encephalopathies.Deutsche Bank adjuste","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0109394709.USD","LU0320765992.SGD","BK4139","BK4135","BK4160","DBRG","BK4205","LU0889565916.HKD","PRAX","BK4233","PCSC"],"gpt_icon":0},{"id":"2589814643","title":"Praxis' Epilepsy Drug Too Good To Continue, FDA Meeting Up Next","url":"https://stock-news.laohu8.com/highlight/detail?id=2589814643","media":"Benzinga","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589814643?lang=en_us&edition=fundamental","pubTime":"2025-12-06 02:10","pubTimestamp":1764958200,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines Inc.  stock rose Friday after the company shared results from the registrational cohort of the EMBOLD study evaluating relutrigine for the treatment of patients with SCN2A and SCN8A developmental and epileptic encephalopathies .The Data Monitoring Committee recommended stopping the study early for efficacy.The FDA has confirmed a meeting to review the data and discuss next steps in the coming weeks. Praxis will make a determination on the timing for filing an NDA for relutrigine after the meeting.The EMBOLD topline results will be presented at the American Epilepsy Society Annual Meeting at the Georgia World Congress Center on Saturday.On Thursday, Praxis Precision Medicines also completed its pre-NDA  meeting with the FDA, including receipt of written feedback and an in-person meeting.Praxis has gained alignment from the agency on the content of the NDA and expects to complete its NDA submission in early 2026.PRAX Price Action: Praxis Precision Medicine shar","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/05/Praxis-Precision-Medicines--Inc-.jpeg?optimize=medium&dpr=2&auto=webp&width=630","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/05/Praxis-Precision-Medicines--Inc-.jpeg?optimize=medium&dpr=2&auto=webp&width=630"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/12/49237801/praxis-epilepsy-drug-too-good-to-continue-fda-meeting-up-next","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/12/49237801/praxis-epilepsy-drug-too-good-to-continue-fda-meeting-up-next","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["LU0320765992.SGD","LU0889565916.HKD","PRAX","LU0109394709.USD","BK4139"],"gpt_icon":0},{"id":"2589278811","title":"Global Equities Roundup: Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2589278811","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589278811?lang=en_us&edition=fundamental","pubTime":"2025-12-06 01:44","pubTimestamp":1764956640,"startTime":"0","endTime":"0","summary":"The latest Market Talks covering Equities. Published exclusively on Dow Jones Newswires throughout the day.1223 ET - Things are looking up for Praxis Precision Medicines after the biopharma company moved closer to filing a New Drug Application for ulixacaltamide and reported positive interim results for a trial of relutrigine. The pre-NDA meeting with the Food and Drug Administration on ulixacaltamide removes some regulatory risk, Oppenheimer analysts write in a note. The interim data on relutrigine could also advance the timeline for an NDA by about six months. \"2026 represents a potentially transformational year for PRAX's long-term growth prospects,\" they write. Shares are up 30%.1159 ET - BRP beat 3Q expectations and provided stronger-than-anticipated guidance for the 4Q and fiscal 2027. Citi analyst James Hardiman says in a report that BRP's managed its inventory effectively despite tariffs, economic uncertainty, and aggressive promotions by competitors. The analyst says the Ski-D","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0942090050.USD","LU0882574139.USD","IE00BQXX3C00.GBP","LU1429558221.USD","BK4548","LU1046421795.USD","LU1674673428.USD","BK4566","LU1435385759.SGD","LU2552382215.SGD","LU2237957902.USD","IE00B19Z8W00.USD","IE00BQXX3D17.EUR","LU0672654240.SGD","LU2357305700.SGD","LU0210533765.USD","LU1814569148.SGD","BK4507","LU0256863811.USD","LU2264538146.SGD","LU1127390331.HKD","LU1823568750.SGD","LU0006306889.USD","LU0868494617.USD","LU1989764664.SGD","IE00B19Z9505.USD","NFLX","SGXZ81514606.USD","LU1548497426.USD","LU0106261372.USD","LU1988902786.USD","LU0079474960.USD","IE00BQXX3F31.USD","LU1720051017.SGD","LU0256863902.USD","BK4108","LU0203202063.USD","SHOP","BK4532","LU2108987350.USD","LU2237957811.SGD","IMAX","LU2461242641.AUD","LU1035775433.USD","SGXZ99366536.SGD","LU2326559502.SGD","LU2552382058.USD","LU1064131342.USD","BK4588","LU0225283273.USD","LU2362540622.SGD","BK4534","LU1720051108.HKD","LU1267930730.SGD","SG9999004303.SGD","SGXZ51526630.SGD","LU0097036916.USD","LU0320765059.SGD","IE00BKPKM429.USD","IE00B19Z8X17.USD","LU2361044949.HKD","LU2087625088.SGD","LU0868494708.USD","LU0109391861.USD","LU0082616367.USD","LU2362541273.HKD","PRAX","LU1316542783.SGD","BK4598","LU0353189680.USD","LU2362541513.USD","LU0077335932.USD","LU0203201768.USD","LU0353189763.USD","LU2860962120.EUR","BK4581","LU0708995401.HKD","LU1674673691.USD","LU2361045086.USD","LU0127658192.USD","BK4587","LU0417517546.SGD","LU0215105999.USD","SGXZ23171101.USD","BK4551","BK4527","LU0642271901.SGD","LU2361044865.SGD","LU0786609619.USD","LU2896262040.SGD","LU1778281490.HKD","IE00BZ1G4Q59.USD","LU1232071149.USD","LU1366192091.USD","IE00BKVL7J92.USD","BK4524","LU2552382132.HKD","LU2543165471.USD","LU0234570918.USD","BK4585","LU0234572021.USD","LU0210536198.USD","LU1069344957.HKD","LU0719512351.SGD"],"gpt_icon":1},{"id":"2589165438","title":"BUZZ-U.S. STOCKS ON THE MOVE-Praxis, EUDA Health, Humana","url":"https://stock-news.laohu8.com/highlight/detail?id=2589165438","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589165438?lang=en_us&edition=fundamental","pubTime":"2025-12-05 23:43","pubTimestamp":1764949388,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Praxis, EUDA Health, HumanaEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: https:","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nL6N3XB0V1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4608","BK4561","BK4136","BK4566","BK4116","LU0274383776.USD","BK4170","BK4500","GB00BDT5M118.USD","LU0266512127.USD","BK4097","BK4534","LU0345780950.USD","LU2125909916.SGD","LU0889565916.HKD","BK4196","LU0070302665.USD","BK4515","BK4585","LU0345781412.USD","LU0368265764.SGD","LU1280957306.USD","LU1923622291.USD","LU0985481810.HKD","LU1093756168.USD","LU0300736492.USD","BK4198","BK4094","LU0330918003.SGD","LU1093756325.SGD","LU1165135440.EUR","SG9999001143.SGD","BK4539","LU2272731600.USD","LU0630314457.HKD","SG9999014021.USD","BK4161","LU1559883803.SGD","IE00BZ199S13.USD","LU0390134368.USD","LU0417517546.SGD","BK4120","BK4551","BK4570","LU0471298777.SGD","IE00B7SZLL34.SGD","LU0654597011.USD","BK4211","IE00BD6J9T35.USD","LU2286300806.USD","BK4187","LU0320765992.SGD","LU0321505868.SGD","IE0002270589.USD","LU2308191902.HKD","LU1023059493.AUD","LU0612318385.USD","BK4154","LU0648001328.SGD","BK4105","BK4542","BK4588","LU0471298694.HKD","BK4157","LU0345780281.USD","LU1721427968.SGD","LU1543694498.USD","BK4008","LU0238689110.USD","LU2125909759.SGD","LU0211331839.USD","LU1201861249.SGD","LU0456854461.SGD","LU1169589451.USD","LU0130102774.USD","LU0225771236.USD","LU0498741890.SGD","LU0061475181.USD","LU0170899867.USD","LU2360106947.USD","LU0306806265.USD","LU0477156953.USD","EUDA","LU0075056555.USD","LU0823411888.USD","LU0053671581.USD","LU1721428347.USD","LU0109394709.USD","LU0306807586.USD","LU0788108826.HKD","LU0348723411.USD","LU1169590202.USD","BK4560","BK4519","LU1992135399.USD","LU0788109121.HKD","LU2506952410.USD","BK4023","BK4007","LU0724618789.USD","LU1983260115.SGD","LU0640476718.USD","LU0498741114.HKD","LU0055631609.USD","IE00B19Z3581.USD","BK4166","LU2477742899.HKD","LU0385154629.USD","LU0566484027.USD","LU0225284248.USD","LU0278409577.USD","LU0006061336.USD","LU0300736062.USD","LU2506952337.HKD","HUM","LU0208291251.USD","BK4017","LU1883866441.USD","LU0266512473.USD","LU1992135472.HKD","LU0345780521.USD","LU1223082196.USD","LU0320765489.SGD","BK4108","LU1878469433.USD","SG9999014013.SGD","LU0496367417.USD","BK4598","BK4125","LU0130517989.USD","BK4613","BK4096","IE00B19Z3B42.SGD","LU2462611646.USD","LU2065731478.USD","LU0054578231.USD","BK4123","LU0612318971.USD","LU1223082519.USD","BK4200","BK4535","BK4533","LU0321505439.SGD","LU2498475776.HKD","BK4139","LU1223083913.SGD","LU0980610538.SGD","BK4532","LU0256863811.USD","PRAX","BK4567","SG9999014005.SGD","BK4549","LU2211815571.USD","BK4554","LU0266013472.USD","LU1430597077.USD","LU2272731782.SGD","LU0149725797.USD"],"gpt_icon":0},{"id":"2589818553","title":"BUZZ-Praxis jumps on positive meeting with FDA for tremor drug, epilepsy trial success","url":"https://stock-news.laohu8.com/highlight/detail?id=2589818553","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589818553?lang=en_us&edition=fundamental","pubTime":"2025-12-05 21:59","pubTimestamp":1764943162,"startTime":"0","endTime":"0","summary":"BUZZ-Praxis jumps on positive meeting with FDA for tremor drug, epilepsy trial success** Shares of drug developer Praxis Precision Medicines PRAX.O rise 31% to $249.27 premarket** Co late on Thursday said U.S. FDA has agreed on NDA for its tremor drug, ulixacaltamide** NDA stands for \"New Drug Application\"** Co also reported positive interim results for its rare epilepsy treatment, relutrigine** \"Preliminary checks suggest peak sales could exceed $2.5 billion and sees meaningful catalysts ahead, including NDA acceptance and potential approval in 2026” - Jefferies ** Co's ulixacaltamide showed meaningful benefit for essential tremor, a condition causing involuntary shaking ** Up to last close, stock up ~147% YTD   ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nL4N3XB12X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","BK4139","PRAX","LU0889565916.HKD","LU0320765992.SGD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.praxismedicines.com","stockEarnings":[{"period":"1week","weight":0.4052},{"period":"1month","weight":0.558},{"period":"3month","weight":5.6357},{"period":"6month","weight":4.9047},{"period":"1year","weight":2.7422},{"period":"ytd","weight":2.3989}],"compareEarnings":[{"period":"1week","weight":0.0054},{"period":"1month","weight":0.009},{"period":"3month","weight":0.0455},{"period":"6month","weight":0.1517},{"period":"1year","weight":0.1406},{"period":"ytd","weight":0.1732}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase IIb clinical trial for the treatment of essential tremor, as well as in Phase II clinical trial to treat Parkinson's disease; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. Praxis Precision Medicines, Inc. was incorporated in 2015 and is based in Boston, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":0.344924},{"month":2,"riseRate":0.2,"avgChangeRate":-0.21435},{"month":3,"riseRate":0.2,"avgChangeRate":-0.183614},{"month":4,"riseRate":0.2,"avgChangeRate":-0.018417},{"month":5,"riseRate":0.4,"avgChangeRate":-0.124101},{"month":6,"riseRate":0.4,"avgChangeRate":-0.094382},{"month":7,"riseRate":0.6,"avgChangeRate":0.167978},{"month":8,"riseRate":0.4,"avgChangeRate":0.080633},{"month":9,"riseRate":0.6,"avgChangeRate":0.013557},{"month":10,"riseRate":0.6,"avgChangeRate":0.512334},{"month":11,"riseRate":0.666667,"avgChangeRate":0.073478},{"month":12,"riseRate":0.833333,"avgChangeRate":0.178493}],"exchange":"NASDAQ","name":"Praxis Precision Medicines, Inc.","nameEN":"Praxis Precision Medicines, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Praxis Precision Medicines, Inc.(PRAX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Praxis Precision Medicines, Inc.(PRAX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Praxis Precision Medicines, Inc.,PRAX,Praxis Precision Medicines, Inc.股票,Praxis Precision Medicines, Inc.股票老虎,Praxis Precision Medicines, Inc.股票老虎国际,Praxis Precision Medicines, Inc.行情,Praxis Precision Medicines, Inc.股票行情,Praxis Precision Medicines, Inc.股价,Praxis Precision Medicines, Inc.股市,Praxis Precision Medicines, Inc.股票价格,Praxis Precision Medicines, Inc.股票交易,Praxis Precision Medicines, Inc.股票购买,Praxis Precision Medicines, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Praxis Precision Medicines, Inc.(PRAX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Praxis Precision Medicines, Inc.(PRAX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}